Understanding Study Evidence: A Plain Guide to Reading Clinical Studies

Maybe you saw a headline that says a supplement ‘works’, or a friend sent you a study that sounds convincing. Now you want to know whether that study is strong enough to act on. This guide walks you through those checks in order, using the site’s study guides and published reviews of how study quality varies.

Step 1: Find out what kind of study you are holding

You are at the headline stage, and this is where most confusion starts. Study types are not equal. A review of the low FODMAP diet in a 2017 review in Gut says early research was limited by retrospective design and no comparator groups, and that later well-designed trials followed.

If you want the full picture of the main designs, the site’s guide on clinical study design explains them side by side. The randomized controlled trial guide covers what randomization buys you and where it stops. Observational studies that follow people in daily life are covered in the site’s observational studies guide.

The next question is who was in it.

Step 2: Check who was studied, at what dose and for how long

You may have a study in hand and want to know whether it applies to you. Size and population matter here. A 2017 systematic review of dietary supplement studies on heart rhythm found 26 published studies, with sample sizes from nine to 206 participants. It also reported that more than 30% of the included studies showed some ECG change.

Thin evidence can also look like a pattern. A 2009 systematic review of fibromyalgia risk factors found 21 articles, mostly theoretical reviews and cross-sectional studies, and described the evidence as ‘still scarce and scattered’.

Study size is covered in the site’s guide on sample size and statistical power explains. Exclusions matter too: see what a study that excludes older adults limits.

With the population and dose in view, the next step is the result itself, and what it was measuring.

Step 3: Read the result, not the headline

The number in a headline is one outcome out of many. A 2004 comparative review of psoriasis biologics notes that most of the studies it covered used a 75% improvement score as their main measure. In the psoriasis review, most studies used PASI 75 as their primary measure.

Size of effect also needs context. A 1998 review of diesel exhaust states that epidemiology ‘cannot reliably distinguish between no risk and very little risk’ when relative risks are low, even when they are statistically significant. A 2017 review of abdominal wall blocks says the supporting data ‘can be inconsistent because of heterogeneity of study design’.

The site’s guides on absolute versus relative risk and confidence intervals show how to do that with real numbers. Measures that stand in for outcomes you feel are covered in the guide on surrogate endpoints.

A clear outcome still needs a complete record behind it. That is the next check.

Step 4: Check whether the trial changed, dropped or never posted results

A registered trial is not frozen. You can check the registry record at ClinicalTrials.gov. The site’s guide on finding the amendment record shows where to look when a trial’s details move. The guide on unpublished trial results explains how to trace a finished trial that has no paper.

The site’s guide on publication bias covers that topic. Missing participants matter as well: see the guide on missing data and dropout.

Once you know the record is complete, the next question is who paid for the study and who checked it.

Step 5: Check who paid for the study and whether it was checked first

Many studies list their funder. A funding line tells you who paid, not whether the result is sound. The site’s guide on a manufacturer-funded trial explains what else to check, and the guide on reading the disclosure section shows how to record those facts without deciding on them alone.

Peer review is another layer. The guide on preprints and peer review explains how to tell the two apart when a claim is shared online.

Funding is one side of trust. Safety data is the other, and it is the part readers most often skip.

Step 6: Check the safety data and what regulators do

The reviewed supplement studies varied substantially in sample size and reporting. The site’s guide on trial adverse events explains the denominator, severity and follow-up you need. A 2017 systematic review noted that ‘dietary supplements have no mandate for assessing cardiovascular safety’, which is one reason study quality varies.

A 2023 narrative review reported 79,071 adverse events related to dietary supplements submitted to the FDA‘s CFSAN Adverse Event Reporting System between 2004 and 2021. The review’s authors argue that the oversight has been insufficient. That is the review’s view, not a regulator’s finding.

You now have the tools to read a study. The last step is deciding what to do with what you found.

Step 7: Decide your next step

You have a study and a headline, and you know more about both. Your job now is to decide whether the evidence fits your question. Use this short checklist before you act on any claim.

1. Name the study type and whether it had a comparison group.
2. Note the number of participants, the dose and how long they were followed.
3. Find the main outcome and the absolute numbers behind any percentage.
4. Check the registry for changes, missing results or a missing paper.
5. Record who funded the work and whether it was peer reviewed.
6. Check how many people were assessed for side effects.
7. If a health decision depends on the answer, take these notes to a qualified clinician.

Every guide on this topic

Study design and type

• Clinical study design types: RCTs, observational studies and more.
• How to read a clinical study: a plain-language walk-through.
• Evaluating evidence quality: strength across many studies.
• Randomized controlled trials: the gold standard and its limits.
• Observational studies: cohort, case-control and cross-sectional.
• Meta-analyses and systematic reviews: how studies are combined.
• Meta-analysis heterogeneity: when study results disagree.
• Clinical trial phases: from phase I safety to post-market surveillance.
• Animal studies vs human trials: the translation gap.
• Understanding emerging research: preliminary findings.
• Ingredient evidence vs marketing claims: a consumer’s guide.

Population, dose and size

• Study populations, dosing and outcomes: what the details tell you.
• Study population excludes older adults: what that limits.
• Dose-response relationships: why more is not always better.
• Sample size and statistical power: why small studies mislead.
• P-values and statistical significance: what the number does and does not say.
• The placebo effect in supplement research: what it means for results.
• Bioavailability studies: what the body actually absorbs.
• Vitamin D clinical research landscape: designs, doses and gaps.
• Probiotic clinical evidence: strain, dose and condition.
• Collagen supplement research: skin, joint and bone outcomes.

Outcomes and results

• A study has many outcomes: why the primary one matters.
• Primary and secondary outcomes: what a trial was built to test.
• Primary versus secondary outcome: which result was the target.
• Surrogate endpoints versus outcomes people feel: a reader’s test.
• Surrogate endpoints and biomarkers: clinical outcome limits.
• Surrogate outcomes in trials: a number versus a patient benefit.
• Composite outcomes: which event drove the result.
• Subgroup analyses: a promising result needs caution.
• Subgroup findings: when a difference may be chance.
• Trial subgroup claims in a press release: matching the headline.
• Absolute versus relative risk: the same numbers worked through.
• Relative and absolute risk: how the same result can sound different.
• Number needed to treat: a useful summary with limits.
• Confidence intervals in trial results: range and precision.
• Confidence intervals: the range around an estimate.
• Noninferiority trials: not much worse, explained.
• A noninferiority trial and its margin: what it means for patients.
• Trial comparator choice: placebo, usual care or active treatment.

Bias, dropout and trial conduct

• Per-protocol versus intention-to-treat: two views of one trial.
• Intention-to-treat analysis: original groups explained.
• Low trial adherence: the treatment actually received.
• Interim trial analysis: why early results can change.
• Randomization and allocation concealment: two protections against bias.
• Clinical trial randomization: what it balances and what it cannot.
• Blinding in clinical trials: who knew what, and when.
• Blinded outcome assessment: why it matters.
• Open-label trials: what participants and researchers knew.
• Missing data and participant dropout: questions every summary should answer.
• Missing trial data: why dropout reasons matter.
• Differential dropout: when one group loses more participants.

Protocols, registries and unpublished results

• Trial protocol changes: where to find the amendment record.
• Trial protocol amendments: what changed and why it matters.
• Trial registration changes: comparing the original and final plan.
• Trial registration dates: was the main outcome named first.
• A trial with a protocol but no results: how to trace its status.
• Unpublished trial results: finding the registry and reporting gap.
• Using ClinicalTrials.gov: ongoing and completed studies.
• Publication bias: why negative results rarely appear.
• A clinical study abstract: what to check in the full report.

Funding, peer review and safety

• A trial funded by its manufacturer: what to check beyond the disclosure.
• Industry funding and author conflicts: reading the disclosure section.
• Research funding and conflicts of interest: study independence.
• Preprints and peer review: what has been checked.
• Trial adverse events: denominators, severity and follow-up.
• Adverse events reported as a table: what to compare first.
• Clinical study safety data: adverse events and limitations.

ClinicalStudyConnect.com is a publication. This guide is for education and does not replace care from a qualified professional.

By ClinicalStudyConnect.com Research Desk